OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Annals of Oncology

Topics

Biology

Biochemistry

Mathematics

Chemistry

Medicine

Show all topics

DOI

10.1093/annonc/mdz012

License

CC-BY-NC

Other Formats

PDF